Evidence before indexation
How the Product Atlas is built, reviewed, and kept honest
A public method for separating a useful product identity map from regulatory claims, clinical guidance, and marketing copy.
1 · Scope
An identity map, not a treatment guide
The atlas helps readers distinguish a product family from a named variant, find the recorded manufacturer, understand the operational category used by Aesthetic Pass, and inspect the evidence status attached to that record.
It does not recommend a product, compare clinical performance, provide dosing or injection technique, confirm authenticity, or establish that a product is approved or available in a reader's country. Qualified professionals must use the locally current label, instructions for use, and regulatory record.
What is the recorded identity, who is the recorded maker, and what evidence layer is present?
Which product should be used, how it should be used, or whether it is suitable for a person.
2 · Record model
Three layers prevent false confidence
Breadth layer
A dated copy of the non-sensitive identity fields used by the mobile catalogue: product name, manufacturer, operational category, and any recorded active ingredient. This makes all 492 identities discoverable without presenting them as reviewed facts.
Evidence layer
A curated family profile adds aliases, material class, source scope, checked dates, and an explicit publication decision.
Review layer
A jurisdiction matrix and claim ledger connect every review statement to source IDs, limitations, evidence strength, and a version-specific human sign-off gate.
3 · Sources
Primary evidence is claim-specific
A source is linked only to the field or statement it supports. A manufacturer page can establish brand identity; it cannot, by itself, establish regulatory status in every country. The public JSON exposes the same source IDs used by each jurisdiction finding and claim.
| Priority | Source type | Used for | Not assumed |
|---|---|---|---|
| 1 | Regulator database or decision | Jurisdiction-specific status and record identity | Status in another jurisdiction |
| 2 | Approved label or instructions for use | Exact presentation, composition, and labelled context | Interchangeability with other variants |
| 3 | Official manufacturer material | Brand, family, maker, and source-market context | Independent efficacy or superiority |
| 4 | Operational catalogue snapshot | Discovery and review-queue coverage | Approval, authenticity, safety, or current availability |
Retailer pages, distributor listings, search snippets, social posts, and AI-generated text are not accepted as final evidence for regulatory or clinical claims.
4 · Jurisdiction
No global approval language
Product names, legal classifications, authorised uses, presentations, labels, and availability can differ between countries. Every source carries a jurisdiction or source-market scope. Wording such as “approved,” “authorised,” or “indicated” is eligible only when it is tied to a current, product-specific source for the named jurisdiction.
5 · Publication gates
A profile earns indexation
The code defaults all detail records to noindex. A profile can become indexable only after its publication state is deliberately changed and the automated gate confirms a review-ready evidence dossier plus an approved, named human sign-off for the exact current dataset version. Changing a status flag alone cannot open the gate.
What “qualified reviewer” means: a licensed clinician whose training and experience are relevant to aesthetic products and who can assess whether identity, label, jurisdiction, and limitation wording is clinically misleading.
Current review: Dr. Adi Zoabi · Dermatologist completed named review for all 11 current family dossiers. Profhilo passed after a product-specific TGA record and official IFU closed its source gap. An assignment record alone is never approval; completed decisions are recorded profile by profile.
- 1
Identity reconciled
Family, variant, maker, spelling, aliases, and catalogue match are checked.
- 2
Sources mapped
Each material claim has a primary source and a checked date.
- 3
Jurisdiction scoped
Country-specific status language is tied to the relevant record or label.
- 4
Clinical review complete
A named qualified reviewer signs the generated packet and the version-matched registry record is added.
- 5
Publication decision recorded
The profile is explicitly marked published; neither a data edit nor a sign-off alone can index it.
- 6
Freshness monitored
Material source or product changes trigger re-review and a new dataset version.
6 · Coverage
Current snapshot, including the gaps
- Catalogue identities
- 492
- Manufacturers
- 91
- Operational categories
- 9
- Source-linked profiles
- 11
- Clinically reviewed profiles
- 11
- Visible primary-source gaps
- 0
The current evidence layer contains 21 source-market records and 23 bounded claims. Named approval applies only to the family profiles shown as clinically reviewed; linked catalogue variants remain noindex without variant-specific evidence.
| Operational category | Identities |
|---|---|
| Dermal fillers | 157 |
| Mesotherapy products | 133 |
| Skin boosters / biostimulators | 124 |
| Chemical peels | 48 |
| Fat-dissolving injectables | 20 |
| Neuromodulators | 3 |
| Energy-based devices | 3 |
| Microneedling devices | 2 |
| PRP / PRF systems | 2 |
Counts describe the Aesthetic Pass operational catalogue snapshot on 14 August 2026; they do not estimate the size of any national or global market.
7 · Corrections
Make errors easy to challenge
Correction requests should include the atlas URL, exact disputed field, jurisdiction, and a current primary source. We record material revisions through a new checked date and dataset version. Use the structured Atlas contribution form; never send patient information.
Material public changes are recorded in the release history and diff contract.
This method operates alongside the broader Aesthetic Pass editorial, clinical review, and corrections policy.